Breaking News

ABIVAX in Cuban Vax-Pact

By Kristin Brooks | February 12, 2014

Leverages technologies and product pipelines aimed at advancing therapeutics

Truffle Capital has established ABIVAX, based in Paris, in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (CIGB), which aims to be a global leader in therapeutic vaccines and antivirals. The partnership will leverage both of their existing product pipelines as well as future acquisitions that are currently underway.
ABIVAX specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biopharma companies financed by Truffle Capital (Wittycell, Splicos and Zophis). The CIGB is the largest subsidiary under BioCubaFarma that specializes in the discovery, development and production of vaccines and antivirals. ABIVAX also brings key assets, including complementary technology platforms and an experienced management team.
The most advanced products in the ABIVAX portfolio include: a therapeutic vaccine for chronic hepatitis B from CIGB and Wittycell; a novel anti-viral drug for AIDS from Splicos, an anti-HPV therapeutic vaccine to treat uterine cervix dysplasia and prevent the emergence of cancer from Wittycell, and a novel adjuvant to boost NKT and B cell response from Wittycell. Two vaccines are in Phase IIb development in patients with chronic hepatitis B, and the other is expected to enter Phase I in 2015 for the treatment of chronic infection with human papilloma virus and cervical dysplasia. The adjuvant is in Phase I studies. The company's first antiviral drug to treat AIDS, is scheduled to enter clinical trials in 1Q14. Additional therapeutic vaccines are in preclinical development.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important